ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that it has secured $65M in Series D financing. Johnson & Johnson Innovation – JJDC, Inc. led the round that was backed by a consortium of investors that included Bios Partners, Novartis Venture Fund, and Visionary Ventures, amongst others.
"We are grateful to our new and returning investors who are making it possible for the company to achieve its vision of helping patients see the future," commented David Esposito, chief executive officer of ONL Therapeutics. "This new round of funding provides an exciting opportunity for our company to advance the clinical development program for ONL1204."
ONL Therapeutics will continue to work alongside Johnson & Johnson's Specialty Ophthalmology research and development team to provide a forum for sharing input to the company's ongoing clinical development plans.
ONL Therapeutics is the first and only clinical-stage company focused on the unique mechanism ...
